CMB International Investment Management Limited sold 1.22 million shares of BIOCYTOGEN-B (02315) stock at an average of HKD 62.2724 per share on September 8, 2026, involving about HKD 76.03 million.
Prior to the disposal, CMB International Investment Management Limited's long position in BIOCYTOGEN-B was 10.98 million shares, representing 9.91%; following the disposal, the holding changed to 9.76 million shares, with the long position ratio falling to 8.81%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments